Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease
Clinical Kidney Journal · 01.08.2024 · 17 (8)
DOI: 10.1093/ckj/sfae186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 18.06.2024. Verfasst von Masatoshi Yoshimoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Center, Toranomon Hospital, Tokyo, Japan. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Okinaka Memorial Institute, Ministry of Health, Labour and Welfare.
Abstract (Originalsprache)
Introduction
The DAPA-CKD study showed a protective effect of dapagliflozin on kidney function in chronic kidney disease (CKD) patients with and without diabetes mellitus. Although dapagliflozin is expected to be effective also in CKD patients with autosomal dominant polycystic kidney disease (ADPKD), its efficacy and safety in this population remain unknown because ADPKD was an exclusion criterion in the DAPA-CKD study. Therefore, we evaluated the effects of dapagliflozin in CKD patients with ADPKD.
Methods
We performed a retrospective observational study of seven patients with ADPKD treated with dapagliflozin at Toranomon Hospital, Tokyo, Japan. We analyzed changes in estimated glomerular filtration rate (eGFR) slope and annual height-corrected total kidney volume before and after starting dapagliflozin treatment.
Results
The median observation period after starting dapagliflozin was 20 months. Four patients received concomitant tolvaptan. The eGFR slope before and after initiation of dapagliflozin could be calculated in six patients and improved in all of them except the one who did not receive a renin-angiotensin system (RAS) inhibitor. Annual height-corrected total kidney volume increased in all patients. Concurrent tolvaptan treatment had no effect.
Conclusion
In CKD patients with ADPKD, dapagliflozin may increase kidney volume but may have a protective effect on kidney function when used concomitantly with RAS inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology Center, Toranomon Hospital, Tokyo, Japan.
- Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
- Department of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
ORCID-Profile: Akinari Sekine, Yuki Oba, Masayuki Yamanouchi, Naoki Sawa
Förderung
- Okinaka Memorial Institute
- Ministry of Health, Labour and Welfare
Zitieren
APA
Yoshimoto, M., Sekine, A., Suwabe, T., Oba, Y., Mizuno, H., Yamanouchi, M., Ubara, Y., Hoshino, J., Inoue, N., Tanaka, K., Hasegawa, E., Sawa, N., & Wada, T. (2024). Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease. Clinical Kidney Journal, 17(8). https://doi.org/10.1093/ckj/sfae186
Vancouver
Yoshimoto M, Sekine A, Suwabe T, Oba Y, Mizuno H, Yamanouchi M, et al. Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease. Clinical Kidney Journal. 2024;17(8). doi:10.1093/ckj/sfae186
BibTeX
@article{Yoshimoto2024,
author = {Yoshimoto, Masatoshi and Sekine, Akinari and Suwabe, Tatsuya and Oba, Yuki and Mizuno, Hiroki and Yamanouchi, Masayuki and Ubara, Yoshifumi and Hoshino, Junichi and Inoue, Noriko and Tanaka, Kiho and Hasegawa, Eiko and Sawa, Naoki and Wada, Takehiko},
title = {Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease},
journal = {Clinical Kidney Journal},
year = {2024},
volume = {17},
number = {8},
doi = {10.1093/ckj/sfae186}
}
EUVIMED